Premium
Post‐treatment Fertility in Patients with Testicular Cancer.: II. Influence of Cis‐platin‐based Combination Chemotherapy and of Retroperitoneal Surgery on Hormone and Sperm Cell Production
Author(s) -
FOSSÅ SOPHIE D.,
OUS S.,
ÅBYHOLM T.,
NORMAN N.,
LOEB M.
Publication year - 1985
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1985.tb06426.x
Subject(s) - azoospermia , medicine , spermatogenesis , discontinuation , testicular cancer , chemotherapy , urology , testosterone (patch) , gynecology , fertility , hormone , infertility , biology , pregnancy , environmental health , population , genetics
Summary— Active sperm production was observed in 20 of 35 patients with testicular cancer 1 year after discontinuation of all treatment (retroperitoneal surgery only: 13; cis‐platin‐based chemotherapy (CVB) ± other treatment: 22). The percentage of patients who regained spermatogenesis increased slightly after a further 1 to 2 years. Fourteen patients (of 121 under observation) impregnated their wives (after retroperitoneal surgery: 9; after CVB ± other therapy: 5). The individual serum FSH values correlated significantly with the results of sperm analysis: an FSH value ≥20 iu/l indicated azoospermia in 8 of 12 patients, whereas only 5 of 30 patients with FSH levels ≤12 iu/l were azoospermic. Serum testosterone and pituitary serum LH were virtually unaffected by the treatment. In conclusion, 1 to 3 years after cis‐platin‐based multi‐modality treatment for testicular cancer, 50 to 60% of patients have active spermatogenesis and fatherhood can be achieved by a significant number of them.